Type 1 Diabetes
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 1 diabetes. There are 2 parts to this study. In Part A, the study treatment will be given by injection just under the skin (subcutaneously). In Part B, the study treatment will be given by an insulin pump.
Your participation could last about 5 weeks and include up to 4 visits to the study center in each of the 2 parts of the study.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participants must have been diagnosed with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
Participants must have a glycated hemoglobin (hemoglobin A1c) <10.0%
Participants must not be receiving any oral or injectable medication intended to treat diabetes other than insulin in the 12 months prior to screening
Participants must not have had more than one episode of severe low blood sugar requiring emergency treatment in the last 6 months
Participants must not have clinically significant blood, kidney, heart, liver, or gastrointestinal disease; cancer; a certain type of disease of the retina in the eye; uncontrolled celiac disease; uncontrolled thyroid disease; or adrenal insufficiency